About: Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
Creator	Du, Lanying Jiang, Shibo Peng, Bi-Hung Tai, Wanbo Algaissi, Abdullah Agrawal, Anurodh Pollet, Jeroen Strych, Ulrich Tseng, Chien-Te Hotez, Peter Bottazzi, Maria Naceanceno, Kevin Peak Nyon, Mun Seid, Christopher
source	Elsevier; Medline; PMC
abstract	Abstract Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 2040 patients and caused 712 deaths since its first appearance in 2012, yet neither pathogen-specific therapeutics nor approved vaccines are available. To address this need, we are developing a subunit recombinant protein vaccine comprising residues 377–588 of the MERS-CoV spike protein receptor-binding domain (RBD), which, when formulated with the AddaVax adjuvant, it induces a significant neutralizing antibody response and protection against MERS-CoV challenge in vaccinated animals. To prepare for the manufacture and first-in-human testing of the vaccine, we have developed a process to stably produce the recombinant MERS S377-588 protein in Chinese hamster ovary (CHO) cells. To accomplish this, we transfected an adherent dihydrofolate reductase-deficient CHO cell line (adCHO) with a plasmid encoding S377-588 fused with the human IgG Fc fragment (S377-588-Fc). We then demonstrated the interleukin-2 signal peptide-directed secretion of the recombinant protein into extracellular milieu. Using a gradually increasing methotrexate (MTX) concentration to 5 μM, we increased protein yield by a factor of 40. The adCHO-expressed S377-588-Fc recombinant protein demonstrated functionality and binding specificity identical to those of the protein from transiently transfected HEK293T cells. In addition, hCD26/dipeptidyl peptidase-4 (DPP4) transgenic mice vaccinated with AddaVax-adjuvanted S377-588-Fc could produce neutralizing antibodies against MERS-CoV and survived for at least 21 days after challenge with live MERS-CoV with no evidence of immunological toxicity or eosinophilic immune enhancement. To prepare for large scale-manufacture of the vaccine antigen, we have further developed a high-yield monoclonal suspension CHO cell line.
has issue date	2018-03-27(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2018.02.065
bibo:pmid	29496347
has license	els-covid
sha1sum (hex)	39f8fc7fe362f52cdef1d3b637989901fa41f8fc
schema:url	https://doi.org/10.1016/j.vaccine.2018.02.065
resource representing a document's title	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
has PubMed Central identifier	PMC5860679
has PubMed identifier	29496347
schema:publication	Vaccine
resource representing a document's body	covid:39f8fc7fe362f52cdef1d3b637989901fa41f8fc#body_text
is schema:about of	named entity 'IgG' named entity 'MERS' named entity 'ENGINEERING' named entity 'CHO CELL' named entity 'INTERLEUKIN-2 ' named entity 'VACCINATED' named entity 'APPROVED' named entity 'DEVELOPING' named entity 'VACCINE' named entity 'FC FRAGMENT' named entity 'SPIKE PROTEIN' named entity 'NEITHER' named entity 'HUMAN IGG' named entity 'METHOTREXATE' named entity 'CHINESE HAMSTER' named entity 'FUSED WITH' named entity 'OVARY' named entity 'RECOMBINANT PROTEIN' covid:arg/39f8fc7fe362f52cdef1d3b637989901fa41f8fc named entity 'CORONAVIRUS VACCINE' named entity 'TO PREPARE' named entity 'ADDAVAX' named entity 'DIRECTED' named entity 'CELL LINE' named entity 'ITS' named entity 'CELLS' named entity 'DEFICIENT' named entity 'RECOMBINANT' named entity 'HAVE' named entity 'CELL LINE' named entity 'MERS' named entity 'SUBUNIT' named entity 'ENCODING' named entity 'EXPRESSION' named entity 'VACCINE ANTIGEN' named entity 'APPEARANCE' named entity 'SIGNIFICANT' named entity 'PRODUCE' named entity 'CAUSED' named entity 'EXTRACELLULAR' named entity 'STABLE' named entity 'PATHOGEN' named entity 'PLASMID' named entity 'BINDING' named entity 'DIHYDROFOLATE REDUCTASE' named entity 'SECRETION' named entity 'CHALLENGE' named entity 'MANUFACTURE' named entity 'CHO CELL' named entity 'PROCESS' named entity 'PROTEIN ' named entity 'SPECIFIC' named entity 'ADHERENT' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'ANIMALS' named entity 'AVAILABLE' named entity 'SIGNAL PEPTIDE' named entity 'TESTING' named entity 'CONCENTRATION' named entity 'HUMAN' named entity 'ADDRESS' named entity 'PROTECTION' named entity 'ADJUVANT' named entity 'PROTEIN RECEPTOR' named entity 'USING' named entity 'INFECTED' named entity 'THERAPEUTICS' named entity 'NEED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software